Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study

We conducted a multicenter, randomized, double‐blind, placebo‐controlled, phase IIb/III study (CASSIOPEIR) using a renal composite endpoint (i.e., doubling of SCr or end‐stage renal disease) in seven Asian countries/region. CASSIOPEIR compared TRK‐100STP (120 μg and 240 μg) with placebo in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurumatani, Hajimu, Okada, Kiyonobu, Origasa, Hideki, Fujita, Toshiro, Isono, Masanao, Nakamoto, Hidetomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451904/
https://www.ncbi.nlm.nih.gov/pubmed/33340238
http://dx.doi.org/10.1111/1744-9987.13616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451904/
https://www.ncbi.nlm.nih.gov/pubmed/33340238
http://dx.doi.org/10.1111/1744-9987.13616

Ejemplares similares